SAUL: This phase III trial is assessing the safety of atezolizumab (an immunotherapy drug) as second line treatment for patients with advanced cancer of the urinary tractAn open label, single arm, multicentre, safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract

Exclusion

• Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract

• Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation

  1. Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
  2. Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
• Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
• Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
• Significant renal disorder indicating a need for renal transplant